Advanced Oncology Certified Nurse Practitioner (AOCNP) Certification Practice Test 2026 - Free AOCNP Practice Questions and Study Guide

The primary use of white blood cell growth factors in oncology is to prevent or treat chemotherapy-induced neutropenia. Neutropenia is a common and serious side effect of chemotherapy, which can lead to an increased risk of infections due to a decreased white blood cell count. White blood cell growth factors, such as granulocyte colony-stimulating factor (G-CSF), stimulate the bone marrow to produce more neutrophils, thereby increasing the white blood cell count and enhancing the patient's ability to fight infections that often occur as a result of chemotherapy.

By using these growth factors, healthcare providers can reduce the incidence of febrile neutropenia, which is a potentially life-threatening condition characterized by fever and a significant reduction in neutrophils. This approach not only helps improve patient outcomes by allowing for more consistent administration of chemotherapy but also enhances the quality of life for patients undergoing treatment.

Other choices address different aspects of oncology care. For instance, enhancing the immune response to infections is more related to immunotherapy strategies rather than specifically targeting neutrophil counts. Improving appetite and managing chronic pain are important considerations in oncology care, but they do not directly relate to the function or purpose of white blood cell growth factors. Thus, the specific role of these growth factors